A unique industry-academia partnership will increase the rate at which promising drug compounds can be tested as potential treatments for amyotrophic lateral sclerosis (ALS), a disease with no known cure that affects 200,000 people worldwide. The partnership between The Montreal Neurological Institute and Hospital (MNI) and Takeda Pharmaceutical Company Limited (Takeda) will allow compounds developed by Takeda scientists to be tested on cell lines produced at the MNI.
Existing infrastructure at the MNI provides great potential for developing effective ALS treatments. In December 2016, The Neuro created the Tanenbaum Open Science Institute (TOSI), a bold initiative to facilitate the sharing of neuroscience findings worldwide to accelerate the discovery of new therapeutics for neurological diseases. At the heart of TOSI are two important platforms, The Open Science Clinical Biologic Imaging and Genetic Repository (C-BIGR) and the Open Drug Discovery Platform.